RBOT: Director Granted 8,003 Options at $7.61 Strike — Form 4
Vicarious Surgical director Ahmad Fuad acquired a stock option on June 27, 2025 giving the right to purchase 8,003 Class A common shares at an exercise price of $7.61.
Rhea-AI Filing Summary
Vicarious Surgical director Ahmad Fuad acquired a stock option on June 27, 2025 giving the right to purchase 8,003 Class A common shares at an exercise price of $7.61. The option is reported as directly beneficially owned and has an expiration date of June 26, 2035.
The filing states the shares underlying the option will vest on June 27, 2026 (or one day prior to the issuer's next annual meeting), subject to continued service. The Form 4 was executed by an attorney-in-fact on August 11, 2025. The disclosure shows a routine director option grant with defined exercise price, vesting schedule, and expiration; no sales or dispositions are reported here.
Positive
- Director Ahmad Fuad acquired 8,003 stock options reported on 06/27/2025 with clear terms disclosed
- Vesting is specified (vesting on 06/27/2026 or one day prior to the next annual meeting), providing transparency on service conditions
- Exercise price and expiration are disclosed (exercise price $7.61, expiration 06/26/2035), clarifying potential future dilution timing
Negative
- None.
Insights
TL;DR: Director received a standard option grant for 8,003 shares at $7.61, vesting in one year — routine disclosure with limited standalone market impact.
The Form 4 documents an acquisition of a stock option by Director Ahmad Fuad on 06/27/2025 for 8,003 underlying Class A shares at a $7.61 exercise price, expiring 06/26/2035. The filing clarifies the vesting date (06/27/2026 or one day before the next annual meeting) and that ownership is direct. From a securities perspective, this is a routine officer/director compensation disclosure required under Section 16 and, by itself, does not signal a material change in company valuation or capital structure.
TL;DR: Disclosure shows a time‑based retention/compensation award to a director; documented vesting and expiration dates provide transparency but are not material alone.
The filing provides clear terms: grant date 06/27/2025, vesting by 06/27/2026 subject to continued service, exercise price $7.61, and expiration 06/26/2035. Such option grants to directors are common as alignment and retention mechanisms. The Form 4 meets Section 16 reporting requirements and offers investors transparent documentation of director compensation timing and potential dilution, though it does not disclose any immediate exercise or sale activity.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 8,003 | $0.00 | $0.00 |
Footnotes (1)
- F1. All of the shares underlying this option will vest on June 27, 2026, or one day prior to the Issuer's next Annual Meeting of Shareholders, whichever is earlier, subject to the Reporting Person's continued service through the applicable vesting date.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What transaction did Ahmad Fuad report on the Form 4 for RBOT?
What is the exercise price and expiration of the option reported by RBOT director?
When do the options vest according to the filing?
What is the reported ownership form for the acquired derivative securities?
Who signed the Form 4 and when was it executed?
AI-generated analysis. How Rhea-AI works. Not financial advice.